Low all-cause mortality in the volunteer-based Rotterdam section of the European randomised study of screening for prostate cancer: Self-selection bias?

Journal of Medical Screening

Volumn 11, Issue 2, 2004, Pages 89-92

  Otto, S J ^a   Schroder F H ^a   De Koning, H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CAUSE OF DEATH; CONTROLLED STUDY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; SAMPLING; SELF EVALUATION;

AGED; COHORT STUDIES; EUROPE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATIC NEOPLASMS; SELECTION BIAS;

EID: 3042604543     PISSN: 09691413     EISSN: None     Source Type: Journal    
DOI: 10.1258/096914104774061074     Document Type: Article

References (14)

1. Globocan 2000. Cancer Incidence, Mortality and Prevalence Worldwide. In: Version 1.0. ed. Lyon: IARC Press 2001: 2001.
2. Auvinen A, Rietbergen JB, Denis LJ, et al. Prospective evaluation plan for randomised trials of prostate cancer screening. The International Prostate Cancer Screening Trial Evaluation Group. J Med Screen 1996;3:97-104.
3. IPSTEG. Rationale for randomised trials of prostate cancer screening. The International Prostate Screening Trial Evaluation Group. Eur J Cancer 1999;35:262-71.
4. de Koning HJ, Auvinen A, Berenguer Sanchez A, et al. Large-scale randomised prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 2002;97:237-44.
5. Nijs HG, Tordoir DM, Schuurman JH, et al. Randomised trial of prostate cancer screening in The Netherlands: assessment of acceptance and motives for attendance. J Med Screen 1997;4:102-6.
6. Essink-Bot ML, de Koning HJ, Nijs HGT, et al. Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst 1998;90:925-31.
7. Beemsterboer PM, de Koning HJ, Kranse R, et al. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam. J Urol 2000;164:1216-20.
8. Otto SJ, van der Cruijsen IW, Liem MK, et al. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer 2003;105:394-9.
9. Hennekens CH, Buring JE. Analysis of epidemiology studies: evaluating the role of confounding. In: Mayrent SL, ed. Epidemiology in medicine. Boston: Little, Brown & Company; 1987:287-323.
10. Esteve J, Benhamou E, Raymond L. Descriptive epidemiology. Lyon: IARC Scientific Publications; 1994: no. 128.
11. Nystrom L, Larsson LG, Wall S, et al. An overview of the Swedish randomised mammography trials: total mortality pattern and the representivity of the study cohorts. J Med Screen 1996;3:85-7.
12. Nijs HG, Essink-Bot ML, DeKoning HJ, et al. Why do men refuse or attend population-based screening for prostate cancer? J Public Health Med 2000;22:312-6.
13. Madalinska JB, Essink-Bot ML, de Koning HJ, et al. Health-related quality of life in patients with screen-detected versus clinically diagnosed prostate cancer preceding primary treatment. Prostate 2001;46:87-97.
14. de Koning HJ, Liem MK, Baan CA, et al. Prostate cancer mortality reduction by screening: Power and time frame with complete enrolment in the European randomised screening for prostate cancer (ERSPC) trial. Int J Cancer 2002;98:268-73.